Company:  FENNEC PHARMACEUTICALS IN ... (FENC)
Form Type:  S-1
Filing Date:  8/10/2017 
CIK:  0001211583 
Address:  PO BOX 13628
68 TW ALEXANDER DRIVE
 
City, State, Zip:  RESEARCH TRIANGLE PARK, North Carolina 27709 
Telephone:  (919) 636-4530 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$10.14  
Change: 
0.07 (0.70%)  
Trade Time: 
Nov 22  
Market Cap: 
$160.92M
Trade FENC now with 

© 2017  
Description of Business
Fennec Pharmaceuticals Inc. ("Fennec," the "Company," "we," "us," or "our") is a biopharmaceutical company focused on the development of Sodium Thiosulfate ("STS") for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA") in September 1996. Effective on August 25, 2011, the Company continued from the Canada Business Corporations Act to the Business Corporations Act (British Columbia) (the "Continuance"). The Continuance was approved by the shareholders of Fennec at the Company's June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have three wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc., a Canadian company. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
Register and access this filing in:     
  FORM S-1
    CALCULATION OF REGISTRATION FEE
    SUBJECT TO COMPLETION, DATED AUGUST 10, 2017
    TABLE OF CONTENTS
    PROSPECTUS SUMMARY
    THE OFFERING
    RISK FACTORS
    USE OF PROCEEDS
    SELLING STOCKHOLDERS
      BENEFICIAL OWNERS
    MATERIAL UNITED STATES AND CANADIAN FEDERAL INCOME TAX ...
    PLAN OF DISTRIBUTION
    DESCRIPTION OF SECURITIES REGISTERED
    INTERESTS OF NAMED EXPERTS AND COUNSEL
    CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
    DESCRIPTION OF BUSINESS
      Competition
      Employees
      DESCRIPTION OF PROPERTY
      LEGAL PROCEEDINGS
    MARKET PRICE OF AND DIVIDENDS ON COMMON EQUITY AND RELATED ...
    Dividend Policy
    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ...
      Liquidity and Capital Resources
      QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
      NAME AND TITLE
    EXECUTIVE COMPENSATION
      COMPENSATION TABLE
      OPTIONS
    Compensation of Directors
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
    Related Party Transactions
    LEGAL MATTERS
      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
      Report of Independent Registered Public Accounting Firm
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        STOCKHOLDERS EQUITY
      Notes to the Consolidated Financial Statements
        STOCKHOLDERS EQUITY
    ADDITIONAL INFORMATION
    PART II
      OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
      UNDERTAKINGS
      EXHIBITS
    SIGNATURES
  EXHIBIT 5.1
  EXHIBIT 10.15
  EXHIBIT 21
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM